EQS-AD-HOC: Heidelberg Pharma AG / keyword (e): contract
Heidelberg Pharma Agreement on the sale of license fees with Healthcare Royalty
13.03.2025 / 00:31 CET / CEST
Publication of an insider information in accordance with Article 17 of Regulation (EU) No. 596/2014, sends an EQS Group service by EQS News.
The issuer / editor is responsible for the content of the message.
Ad -hoc report – Publication of insider information according to Art. 17 of the Regulation (EU) No. 596/2014
Heidelberg Pharma Agreement on the sale of license fees with Healthcare Royalty
- Healthcare Royalty and Heidelberg Pharma fit the agreement on the sale of license fees and Heidelberg Pharma receives immediate payment of USD 20 million
- Heidelberg Pharma extends its liquidity range until 2027
Ladenburg, March 12, 2025 -Heidelberg Pharma AG (FWB: HPA), a biotech company in the clinical phase that developed innovative antibody-active ingredients (ADCS), and Healthcare Royalty (HCRX) today announced that they have signed a change to the original license agreement in March 2024.
The financing agreement from March 2024 and the current change affect the partially Monetarization the future license fees of Heidelberg Pharma from the global sales of TLX250-CDX, a radiopharmaceutical imaging process for the diagnosis and characterization of clear cell cancer using positron emission tomography (PET).
The most important conditions of the changed agreement between Heidelberg Pharma and HCRX are as follows:
- Heidelberg Pharma receives a payment of USD 20 million.
- The sales-dependent milestone of $ 15 million for 2025 is due to later potential market launch of TLX250-CDX; The FDA’s approval decision could take place by August 27, 2025.
- The originally agreed payment of $ 75 million when registered TLX250-CDX by the FDA is on 70 million USD reduced, with further cuts if the FDA approval takes place after the end of 2025.
- The second stage of the two -stage escalating upper limit for cumulative license fees that are sold to HCRX has been increased. When the escalating upper limit has been reached, the license fees flow back to Heidelberg Pharma and HCRX receives a low single -digit percentage of license fees.
Taking into account the agreement with HCRX and the expected payments of $ 90 million to Heidelberg Pharma, the company expects an extended liquidity range until 2027.
End of insider information
Information and explanations of the issuer on this communication:
Via TLX250-CDX
TLX250-CDX is a radioactive form of the girentuximab antibody that binds to the tumor-specific antigen CAIX on clear-cell kidney cell carcinomas. TLX250-CDX could also be suitable for diagnosing other types of tumor using PET. Heidelberg Pharma developed the antibody up to a first completed clinical phase III study before it exhausted it to Telix Pharmaceuticals Limited (Telix), an Australian company based in Melbourne in 2017.
About Heidelberg Pharma
Heidelberg Pharma is a biopharmaceutical company that works on a new treatment approach in oncology and, based on its own ADC technologies, develops new medicines for targeted and highly effective cancer treatment. ADCs are antibody-active ingredient conjugate that combine the specificity of antibodies with the effectiveness of toxins to combat cancer. Selected antibodies are loaded with different active ingredients and transport them into the sick cells. The toxin can have its effect there and kill the cell.
Heidelberg Pharma uses several loading ingredients and has built up an ADC toolbox that overcomes tumor resistance via a variety of ways and addresses different types of cancer via different antibodies. The goal is to develop targeted and highly effective ADCs to treat a variety of malignant hematological and solid tumors.
Heidelberg Pharma is the first to use the active ingredient amanitin from the green tuber mushroom for use in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic approach and is used as an active ingredient in the ADC technology based on an amanitin, the so-called ATAC technology.
The company is based in Ladenburg and is noted on the Frankfurt securities exchange: ISIN DE000A11QVV0 / WKN A11QVV / symbol HPHA. You can find more information at www.heidelberg-pharma.com
Atac® is a registered brand of Heidelberg Pharma Research GmbH.
ITAC ™, ETAC ™ are brand registrations of Heidelberg Pharma Research GmbH.
About Healthcare Royalty
HCRX is a leading company for the takeover of license fees that focuses on commercial or just before the market maturity of biopharmaceutical products. HCRX has invested more than $ 5 billion in over 90 biopharmaceutical products since its foundation and maintains offices in Stamford (CT), San Francisco, Boston, London and Miami. You can find more information at https://www.hcrx.com/.
Healthcare Royalty® and HCRX® Are registered brands of Healthcare Royalty Management, LLC.
| contact Heidelberg Pharma AG Corporate communications Sylvia Wimmer Tel.: +49 89 41 31 38-29 Email: [email protected] Gregor-Mendel-Str. 22, 68526 Ladenburg | IR/PR consulting MC Services AG Katja Arnold (Ciro) Managing Director & Partner Tel.: +49 89 210 228-40 Email: [email protected] |
| Optimum Strategic Communications Mary Clark, Zoe Bolt Email: [email protected] Tel: +44 (0) 20 3882 9621 | |
This text contains certain future -oriented statements that relate to the business area of the company and which are “expected”, “,” in the future “,” possible “,” possible “,” possible “,” in the future “or similar expressions, the plans and intentions of society. Such future -oriented statements include known and unknown risks, uncertainties and other factors that could cause the actual results of the business operations, the financial situation, the earnings, the achievements, the achievements or the results of the sector differ significantly from any future results, yields or achievements, which are expressed or provided in such future -oriented statements. In view of these imponderables, possible investors and partners are warned to support excessive trust in such future -oriented statements. We assume no obligation to update such future -oriented statements in order to reflect future events or developments.
13.03.2025 CET/CEST The EQS Distribution Services include legal reporting obligations, corporate news/financial news and press releases.
Media archive at https://eqs-news.com